# EDGAR Filing Document

**Accession Number:** 0000922247
**File Stem:** 0000000000-23-001112
**Filing Date:** 2023-2
**Character Count:** 3477
**Document Hash:** 188f1cacf5413bcbc979343bf99e24fb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001112.hdr.sgml**: 20230314

**ACCESSION NUMBER**: 0000000000-23-001112

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230202

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cyclo Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000922247
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 593029743
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 6714 NW 16TH STREET, SUITE B
- **CITY:** GAINESVILLE
- **STATE:** FL
- **ZIP:** 32653
- **BUSINESS PHONE:** 386-418-8060

**MAIL ADDRESS:**
- **STREET 1:** PO BOX 1180
- **CITY:** ALACHUA
- **STATE:** FL
- **ZIP:** 32616-1180

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CTD HOLDINGS INC
- **DATE OF NAME CHANGE:** 20000913

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC
- **DATE OF NAME CHANGE:** 19941012

## Text-Extract

```

United States securities and exchange commission logo

                          February 2, 2023

       N. Scott Fine
       Chief Executive Officer
       Cyclo Therapeutics, Inc.
       6714 NW 16th Street, Suite B
       Gainesville, FL 32653

                                                        Re: Cyclo Therapeutics,
Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed January 27,
2023
                                                            File No. 333-269437

       Dear N. Scott Fine:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Alan
Campbell at 202-551-4224 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Zev M. Bomrind, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 2, 2023

N. Scott Fine
Chief Executive Officer
Cyclo Therapeutics, Inc.
6714 NW 16th Street, Suite B
Gainesville, FL 32653

**Re: Cyclo Therapeutics, Inc.**
**Registration Statement on Form S-1**
**Filed January 27, 2023**
**File No. 333-269437**

Dear N. Scott Fine:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Zev M. Bomrind, Esq.